Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
A market commentary pointed to elements UnitedHealth executives had previously laid out, including targeted Medicare margin levels, an “exit” framework, and a repricing timeline, as the stock rally unfolded.
THE APEX TIMES
THE APEX TIMES
A regulator approval announced Aug. 10 gives Eli Lilly’s weight-loss drug a new form factor: a daily pill designed to reach patients who may prefer tablets over injections.
THE APEX TIMES
After reporting a second quarter marked by a large non-cash impairment expense, Pfizer pointed to a higher 2026 outlook and highlighted clinical readouts tied to LITFULO, keeping investors focused on the path to future growth rather than just current earnings.
THE APEX TIMES
CVS Pharmacy says it is widening its direct-to-consumer weight management offerings, highlighting FDA-approved GLP-1 options for customers who use insurance as well as those paying cash, while pairing medication access with care support.
THE APEX TIMES
The purchase, described as adding roughly 38,000 shares, is the latest example of executive insider activity tied to Pfizer’s stock
THE APEX TIMES
The company filed U.S. lawsuits against multiple businesses it says are selling unauthorized products tied to retatrutide, an investigational weight-loss candidate.
THE APEX TIMES
In remarks reported by Yahoo Finance, Novo Nordisk’s chief executive said Eli Lilly is winning more market share even as demand for oral weight-loss treatments accelerates and Lilly’s stock remains under pressure.
THE APEX TIMES
In comments covered from its earnings call, Eli Lilly said revenue rose sharply on strong demand for Mounjaro and Zepbound, prompting an increase to its full-year guidance.
THE APEX TIMES
In a recap of Pfizer’s Q2 discussion with investors, a Yahoo Finance report points to five themes that analysts returned to, even as management portrayed steadier performance in the company’s non-COVID business.
